Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811

Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model

Shao, D., Du, D., Liu, H., Lv, J., Cheng, Y., Zhang, H., Lv, W., Wang, S., & Lu, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2021.721318 · Cited by 13

EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Moore, S. M., & Wheatley‐Price, P. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.004 · Cited by 13

Surgical resection of brain metastases prolongs overall survival in non-small-cell lung cancer.

Yen, C.-T., Wu, W.-J., Chen, Y.-T., Chang, W., Yang, S.-H., Shen, S.-Y., Su, J., & Chen, H. (2021) · PubMed Central · Cited by 13

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis

Chiu, T.-H., Tung, P., Huang, C., Ju, J., Huang, A. C., Wang, C., Ko, H., Hsu, P., Fang, Y., Guo, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-08449-w · Cited by 13

Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis

Yang, X., Zeng, Y., Tan, Q., Huang, Z., Jia, J., & Jiang, G. (2022) · Journal of Immunology Research · doi:10.1155/2022/4518898 · Cited by 13

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation

Nishihara, S., Yamaoka, T., Ishikawa, F., Ohmori, T., Andō, K., Kusumoto, S., Kishino, Y., Manabe, R., Hasebe, Y., Sagara, H., et al. (2022) · Cells · doi:10.3390/cells11142201 · Cited by 13

The Early Impact of the COVID-19 Pandemic on Lung, Colorectal, and Breast Cancer Screening and Treatment at a Tertiary Cancer Center

Lou, J., Kooragayala, K., Williams, J. P., Sandilos, G. A., Butchy, M. V., Yoon‐Flannery, K., Kwiatt, M. E., Hong, Y. K., Shersher, D. D., & Burg, J. M. (2022) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000936 · Cited by 13

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

Mordant, P., Brosseau, S., Milleron, B. J., Santelmo, N., Fraboulet, S. M., Besse, B., Langlais, A., Gossot, D., Thomas, P. A., Pujol, J.-L., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.08.013 · Cited by 13

Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment

Acker, F., Aguinarte, L., Althoff, F., Heinzen, S., Rost, M., Wild, P. J., Reiser, L., Mänz, M., Meyer, F., Stratmann, J., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.019 · Cited by 13

Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities

Kwok, W. C., Lam, D. C. L., Ip, M., Tam, T. C. C., & Ho, J. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001360 · Cited by 13

Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies

Li, L., Huang, Q., Sun, J., Yan, F., Wei, W., Li, Z., Liu, L., & Deng, J. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2132116 · Cited by 13

Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference

Chan, L. S., Liu, J., Li, M. S. C., Li, L., Tao, Q., & Mok, T. S. K. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01454-4 · Cited by 13

Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands

ten Berge, D. M. H. J., Damhuis, R. A. M., Aerts, J. G. J. V., & Dingemans, A. C. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107253 · Cited by 14

Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort

Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01349-1 · Cited by 13

Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

Russo, A., Scilla, K. A., Mehra, R., Gittens, A., McCusker, M. G., de Miguel‐Pérez, D., Gomez, J. E., Peleg, A., Re, M. D., & Rolfo, C. D. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.07.003 · Cited by 13

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study

Banla, L. I., Tzeng, A., Baillieul, J. P., Kandekhar, M. J., Fitzgerald, K., LoPiccolo, J., Poitras, H. A., Soto, D. E., Rotow, J. K., Singer, L., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100559 · Cited by 13

Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer

Stock-Martineau, S., Laurie, K., McKinnon, M., Zhang, T., & Wheatley‐Price, P. (2020) · Current Oncology · doi:10.3390/curroncol28010008 · Cited by 13

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification

Choi, W., Park, S.-Y., Lee, Y., Lim, K. Y., Park, M., Lee, G. K., & Han, J. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2020.1331 · Cited by 13

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations

Ohara, S., Suda, K., & Mitsudomi, T. (2021) · Cells · doi:10.3390/cells10020354 · Cited by 13

Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review

Brouns, A., Dursun, S., Bootsma, G. P., Dingemans, A. C., & Hendriks, L. E. L. (2021) · Cancers · doi:10.3390/cancers13133144 · Cited by 13

Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis

MITSUYA, S., Tsuruoka, K., Kanaoka, K., Funamoto, T., Tsuji, H., Matsunaga, N., Nakamura, T., Tamura, Y., Imanishi, M., IKEDA, S., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15331 · Cited by 13

Deep learning predicts epidermal growth factor receptor mutation subtypes in lung adenocarcinoma

Song, J., Ding, C., Huang, Q.-L., Luo, T., Xu, X., Chen, Z., & Li, S. (2021) · Medical Physics · doi:10.1002/mp.15307 · Cited by 13

First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study

Kudo, K., Nishii, K., Makimoto, G., Ishikawa, N., Tsubata, Y., Kodani, M., Fujimoto, N., Yamasaki, M., Kubota, T., Takigawa, N., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03893-z · Cited by 13

Osimertinib in EGFR -Mutated Advanced NSCLC

Revannasiddaiah, S., Devadas, S. K., & Maka, V. V. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001514 · Cited by 13

Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer

Jassem, J., & Dziadziuszko, R. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30361-3 · Cited by 12

Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors

Xie, Y., Yang, L., Fang, H., Yu, C., Wang, X., Liu, N., Xu, T., Xia, H., & Fang, S. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108593 · Cited by 12

Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer

Fukuda, K., Nanjo, S., Takeuchi, S., Chakrabarti, T., Brown, T. S., Sahadevan, S. W. D., Arai, S., Sato, S., Kotani, H., Nishiyama, A., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.007 · Cited by 12

Mitigation and management of adverse events associated with amivantamab therapy

Florez, N., LeBoeuf, N. R., Rotow, J. K., Marks, J. A., Sabari, J. K., Arrieta, O. G., Baldotto, C. S. D. R., Gosain, R., Zawisza, D., McDonald, S., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf194 · Cited by 12

Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

Le, X., Robichaux, J. P., Nilsson, M. B., Vijayan, R. S. K., Ravichandran, A., Wu, J., Elamin, Y. Y., Hong, L., Pei, J., He, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61817-8 · Cited by 12

Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC)

Kariri, Y. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196960 · Cited by 12

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib

Shi, Y., Lv, D., Feng, W., Liu, C., Xing, P., Yan, Y., Yin, J., Ren, X., Zhang, J., Han, G., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02481-8 · Cited by 12

Yield of tumor samples with a large guide-sheath in endobronchial ultrasound transbronchial biopsy for non-small cell lung cancer: A prospective study

Katsurada, N., TACHIHARA, M. Y., Jimbo, N., Yamamoto, M., Yoshioka, J., Mimura, C., Satoh, H., Furukawa, K., Otoshi, T., Kiriu, T., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259236 · Cited by 12

The treatment of advanced lung adenocarcinoma with activating EGFR mutations

Rocco, D., Gravara, L. D., Battiloro, C., Maione, P., & Gridelli, C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1957096 · Cited by 13

European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review

Shah, R. N. H., Girard, N., Nagar, S. P., Griesinger, F., Roeper, J., Davis, K. L., Karimi, P., Sawyer, W., Yu, N., Taylor, A., et al. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00261-8 · Cited by 12

Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial

Li, C., Hsia, T., Yang, S., Chao, K. S. C., Tu, C., Chen, H.-J., & Li, C.-H. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354221086663 · Cited by 12

EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil

Pinto, I. A., Cavagna, R. D. O., da Silva, A. L. V., Dias, J. M., Santana, I. V., Souza, L. C., da Silva, F. A. F., Fernandes, M. F. B., Pinto, G. D. J., Negreiros, I. S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac167 · Cited by 12

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations

Liu, W., Ren, S., Xiao, Y., Yang, L., Zeng, C., & Hu, Y. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1036334 · Cited by 12

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer

Moonmuang, S., Tantraworasin, A., Orrapin, S., Udomruk, S., Chewaskulyong, B., Pruksakorn, D., & Chaiyawat, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054827 · Cited by 12

Anticancer Evaluation of Novel Benzofuran–Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells

Lee, Y., Lee, S. H., Lee, Y., Song, D., Park, S.-H., Kim, J., Namkung, W., & Kim, I. (2024) · Pharmaceuticals · doi:10.3390/ph17020231 · Cited by 12

Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial

Wells, J. C., Mullin, M. L. L., Ho, C., Melosky, B. L., Laskin, J. J., Wang, Y., & Sun, S. B. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107529 · Cited by 14

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201

Cho, B. C., Han, J., Lee, K. H., Lee, Y., Kim, D., Min, Y. J., Kim, S., Cho, E. K., Kim, J.-H., Lee, G., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107509 · Cited by 12

Clinical Practice Guidelines for Brain Metastasis From Solid Tumors

Sung, K. S. (2024) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2023.0049 · Cited by 12

DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC

Grant, C. E., Flis, A. L., Toulabi, L., Zingone, A., Rossi, E. L., Aploks, K., Sheppard, H., & Ryan, B. M. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13608 · Cited by 12

Current status of molecular diagnostics for lung cancer

Имянитов, Е. Н., Преображенская, Е. В., & Орлов, С. В. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00244 · Cited by 15

Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study

Tibau, A., Hwang, T. J., Avorn, J., & Kesselheim, A. S. (2024) · BMJ · doi:10.1136/bmj-2023-079126 · Cited by 13

Innovative approaches in stem cell therapy: revolutionizing cancer treatment and advancing neurobiology – a comprehensive review

Banerjee, D., Bhattacharya, A., Puri, A. V., Munde, S. V., Mukerjee, N., Mohite, P. B., Kazmi, S. W., Sharma, A., Alqahtani, T., & Shmrany, H. A. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002111 · Cited by 12

Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management

Zhang, H., & To, K. K. W. (2024) · Clinical and Translational Science · doi:10.1111/cts.70053 · Cited by 12

Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review

Nepote, A., Poletto, S., Bertaglia, V., Carnio, S., Piumatti, C., Lanzetta, C., Cantale, O., Saba, G., Bironzo, P., Novello, S., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104540 · Cited by 12

Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study

Serna‐Blasco, R., Mediavilla-Medel, P., Medina, K., Sala, M. Á., Bujanda, D. A., Díaz-Serrano, A., Antoñanzas, M., Ocaña, J., Mielgo-Rubio, X., Fernández, I., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108550 · Cited by 12

Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Angelopoulos, P. A., Passaro, A., Attili, I., Aliaga, P. T., Corvaja, C., Spitaleri, G., Battaiotto, E., Signore, E. D., Curigliano, G., & de Marinis, F. (2025) · Genes · doi:10.3390/genes16070772 · Cited by 12

High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content

Meador, C. B., Milan, M. S. D., Hu, E. Y., Awad, M. M., Rabin, M. S., Paweletz, C. P., Hartmaier, R. J., Laus, G., & Oxnard, G. R. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00420 · Cited by 12

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)

Maansson, C. T., Vad‐Nielsen, J., Meldgaard, P., Nielsen, A. L., & Sørensen, B. S. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13093 · Cited by 12

Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures

Wieleba, I., Wojas‐Krawczyk, K., Krawczyk, P. A., & Milanowski, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042261 · Cited by 12

Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)

Cardona, A. F., Ruíz-Patiño, A., Recondo, G., Martín, C., Raez, L. E., Samtani, S., Minatta, J. N., Blaquier, J. B., Enrico, D. H., Burotto, M., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.001 · Cited by 12

Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer

Kosibaty, Z., Brustugun, O. T., Eide, I. J. Z., Tsakonas, G., Grundberg, O., Petris, L. D., McGowan, M., Hydbring, P., & Ekman, S. (2022) · Cancers · doi:10.3390/cancers14143430 · Cited by 12

An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer

Qi, Y., Xia, X., Shao, L., Guo, L., Dong, Y., Tian, J., Xu, L., Niu, R., & Wei, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.616546 · Cited by 12

Non-small-cell lung cancer: how to manage EGFR-mutated disease

Pecci, F., Cantini, L., Metro, G., Ricciuti, B., Lamberti, G., Farooqı, A. A., & Berardi, R. (2022) · Drugs in Context · doi:10.7573/dic.2022-4-1 · Cited by 12

Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma

Chen, S., Zhang, S., Yuan, Y., Wang, Z., Li, J., Li, T., Zuo, M., Feng, W., Chen, M., & Liu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016520 · Cited by 12

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Yu, W., Chen, Y., Huang, C.-Y., Ye, Z.-H., Shi, W., Zhu, H., Shi, J.-J., Chen, J., & Lu, J.-J. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0934-1 · Cited by 12

The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine

Katzendobler, S., Do, A., Weller, J., Rejeski, K., Dorostkar, M. M., Albert, N. L., Forbrig, R., Niyazi, M., Egensperger, R., Tonn, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1014711 · Cited by 12

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy

Shah, V. S., McNatty, A., Simpson, L., Ofori, H., & Raheem, F. (2023) · Biomedicines · doi:10.3390/biomedicines11030950 · Cited by 12

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations

Zhang, L., You, Y., Liu, X., Liu, F., Nie, K., & Ji, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14880 · Cited by 12

Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small cell lung cancer cells

Zhang, D., Yang, Y., Kang, Y., Xie, D., Zhang, X., & Hao, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-401 · Cited by 12

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors

Ariyasu, R., Kakuto, S., Miyadera, K., Akita, T., Kiritani, A., Tsugitomi, R., Amino, Y., Uchibori, K., Kitazono, S., Yanagitani, N., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100524 · Cited by 12

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators

Volta, F., Monica, S. L., Leonetti, A., Gnetti, L., Bonelli, M. A., Cavazzoni, A., Fumarola, C., Galetti, M., Eltayeb, K., Minari, R., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01005-0 · Cited by 12

CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway

Liu, Y., Tsai, M., Wu, S., Chang, T., & Shih, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122345 · Cited by 12

Clinical and Prognostic Significance of Glutathione Peroxidase 2 in Lung Adenocarcinoma

Hashinokuchi, A., Matsubara, T., Ono, Y., Shunichi, S., Matsudo, K., Nagano, T., Kinoshita, F., Akamine, T., Kohno, M., Takenaka, T., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15116-z · Cited by 12

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis

Bian, D. J. H., Lazaratos, A.-M., Maritan, S. M., Quaiattini, A., Zeng, Z., Zhu, Z., Sener, U. T., Malani, R., Kim, Y. J., Ichihara, E., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29668 · Cited by 12

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC

Uehara, Y., Takeyasu, Y., Yoshida, T., Tateishi, A., Torasawa, M., Hosomi, Y., Masuda, K., Shinno, Y., Matsumoto, Y., Okuma, Y., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100058 · Cited by 12

Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives

Sartori, G., Belluomini, L., Lombardo, F., Avancini, A., Trestini, I., Vita, E., Tregnago, D., Menis, J., Bria, E., Milella, M., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1776119 · Cited by 12

Treating Choroidal Metastases and Improving Vision with Osimertinib in EGFR T790M-Mutated Lung Adenocarcinoma: A Case Report and Review of the Literature

Keshwani, K., Roelofs, K. A., Hay, G. R., Lewis, R., & Plowman, N. (2020) · Ocular Oncology and Pathology · doi:10.1159/000510602 · Cited by 12

Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy

Kim, J. T., Zhang, W., Lopategui, J. R., Vail, E., & Balmanoukian, A. S. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00296 · Cited by 12

Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019

Li, W., Lyu, Y., Wang, S., Zhou, X., Ma, J., Xu, C., Li, F., Ying, J., Guo, L., Qiu, T., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100163 · Cited by 12

The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer

Lengel, H. B., Connolly, J. G., Jones, G. D., Caso, R., Zhou, J. H., Sánchez-Vega, F., Mastrogiacomo, B., Isbell, J. M., Li, B. T., Liu, Y., et al. (2021) · Cancers · doi:10.3390/cancers13153656 · Cited by 12

Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review

Lee, M. H., Patel, D. G., Jofre, S. A., Fidvi, S. A., Suhrland, M. J., Cohen, P. R., & Cheng, H. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.08.002 · Cited by 12

Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system

Perdrizet, K., Stockley, T. L., Law, J. H., Smith, A. C., Zhang, T., Fernandes, R., Shabir, M., Sabatini, P. J. B., Youssef, N. A., Ishu, C., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100534 · Cited by 12

Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer

Rack, S., Feeney, L., Hapuarachi, B. S., Adderley, H., Woodhouse, L. C., Betts, G. N. J., Burghel, G. J., Harrington, K. J., & Metcalf, R. L. (2022) · Cancers · doi:10.3390/cancers14051133 · Cited by 12

High fibrinogen-albumin ratio index (FARI) predicts poor survival in head and neck squamous cell carcinoma patients treated with surgical resection

Wang, S., Feng, Y., Xie, Y., Zhao, X., Ma, J., Liu, X., Hu, C., & Hou, T. (2022) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-022-07391-x · Cited by 12

Resistance is futile with fourth-generation EGFR inhibitors

Marasco, M., & Misale, S. (2022) · Nature Cancer · doi:10.1038/s43018-022-00365-2 · Cited by 12

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

Cho, B. C., Sethi, S., & Spira, A. I. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2414705 · Cited by 12

Cost-Effectiveness Analysis of Comprehensive Genomic Profiling in Patients with Advanced Non–Small-Cell Lung Cancer Using Real-World Data

Spencer, S., Ye, W., Peng, S., & Zou, D. (2025) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2025.05.011 · Cited by 11

Targeting PDK4 to mitigate osimertinib-induced cardiotoxicity: Insights into mitochondria-endoplasmic reticulum crosstalk and necroptosis

Deng, J., Wang, D., Jiang, K., Lang, X., Sun, Y., & Li, Y. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.017 · Cited by 11

Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report

Le, X., Baik, C. S., Cho, B. C., Riess, J. W., Piotrowska, Z., Langen, A. J. D., Goldberg, S. B., Goldman, J. W., Reguart, N., Shiraishi, Y., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.10.009 · Cited by 11

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients

Roosan, M. R., Mambetsariev, I., Pharaon, R. R., Fricke, J., Baroz, A. R., Chao, J., Chen, C., Nasser, M. W., Chirravuri‐Venkata, R., Jain, M., et al. (2021) · Cancers · doi:10.3390/cancers13112776 · Cited by 11

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

Hu, Y. W., Ren, S., Yang, L., Tong, Z., Wang, R., Han, W., Zeng, C., Li, J., Xiao, P., Wang, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.912153 · Cited by 11

Therapeutic potential of the novel Bcl‐2/Bcl‐XL dual inhibitor, APG1252, alone or in combination against non‐small cell lung cancer

Qian, L., Vallega, K. A., Yao, W., Wang, D., Zhai, Y., He, X., & Sun, S. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23458 · Cited by 11

Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors

Sun, S. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0951-0 · Cited by 11

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

Nie, N., Li, J., Zhang, J., Dai, J., Liu, Z., Ding, Z., Wang, Y., Zhu, M., Hu, C., Han, R., et al. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221134735 · Cited by 12

Somatic mutation detection and KRAS amplification in testicular germ cell tumors

Cabral, E. R. M., Pacanhella, M. F., Lengert, A. V. H., dos Reis, M. B., Leal, L. F., de Lima, M. A., da Silva, A. L. V., Pinto, I. A., Reis, R. M., Pinto, M. T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1133363 · Cited by 11

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

Wen, L., Zhen, J., Shan, C., Lai, M., Hong, W., Wang, H., Ye, M., Yang, Y., Li, S., Zhou, Z., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01219-y · Cited by 11

Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system

Yang, C., Shih, J., Liao, W., Ho, C., Hsu, C., Tsai, T.-H., Wu, S., Lin, Y., Hsu, W., Jain, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113310 · Cited by 11

Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer

Bai, Y., Lü, Z., Zhang, C., Guo, M., Xia, L., Tang, Z., Liu, Y., & Deng, S. (2023) · Oncogene · doi:10.1038/s41388-023-02866-5 · Cited by 12

Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer

Ogimoto, T., Ozasa, H., Tsuji, T., Funazo, T. Y., Yamazoe, M., Hashimoto, K., Yoshida, H., Hosoya, K., Ajimizu, H., Nomizo, T., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0371 · Cited by 11

Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?

Poh, M. E., Chai, C.-S., Liam, C. K., Ho, G. F., Pang, Y. K., Hasbullah, H. H., Tho, L. M., Nor, I. M., Ho, K. F., Thiagarajan, M., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-691 · Cited by 11

Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib

Papazyan, T., Denis, M. G., Sagan, C., Raimbourg, J., Herbreteau, G., & Tostivint, E. P. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01072-x · Cited by 11

The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review

Fujiwara, Y., Shimomura, K., Yamaguchi, T., Shimizu, J., Watanabe, N., Matsuzawa, R., Murotani, K., & Horio, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1419256 · Cited by 12

Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials

Olivier, T., Haslam, A., & Prasad, V. K. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1569 · Cited by 11

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review

Podder, V., Ranjan, T., Gowda, M., Camacho, A. M., & Ahluwalia, M. S. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01388-1 · Cited by 12

High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare

Bradley, C. J., Liang, R., Lindrooth, R. C., Sabik, L. M., & Perraillon, M. C. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.4868 · Cited by 11

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer

Shin, J. E., Jung, H. A., Park, S., Sun, J., Lee, S., Ahn, J. S., Ahn, M., & Shim, B. Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-81704-4 · Cited by 13

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

Planchard, D., Janne, P. A., Cheng, Y., Yang, J. C., Yanagitani, N., Kim, S., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306434 · Cited by 772

Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC

Janne, P. A., Planchard, D., Kobayashi, K., Yang, J. C., Liu, Y. L., Valdiviezo, N., Kim, T. M., Jiang, L., Kagamu, H., Yanagitani, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2510308 · Cited by 133

Overall survival with osimertinib in untreated NSCLC

Gourd, E. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30778-8 · Cited by 5

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis

Yi, L., Fan, J., Qian, R., Luo, P., & Zhang, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32097 · Cited by 102